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Blockade of dopamine D2 receptors remains a common feature of all antipsychotics. It has been hypothesized that the extrastriatal
(cortical, thalamic) dopamine D2 receptors may be more critical to antipsychotic response than the striatal dopamine D2 receptors. This
is the first double-blind controlled study to examine the relationship between striatal and extrastriatal D2 occupancy and clinical effects.
Fourteen patients with recent onset psychosis were assigned to low or high doses of risperidone (1 mg vs 4 mg/day) or olanzapine
(2.5 mg vs 15 mg/day) in order to achieve a broad range of D2 occupancy levels across subjects. Clinical response, side effects, striatal
([11C]-raclopride-positron emission tomography (PET)), and extrastriatal ([11C]-FLB 457-PET) D2 receptors were evaluated after
treatment. The measured D2 occupancies ranged from 50 to 92% in striatal and 4 to 95% in the different extrastriatal (frontal, temporal,
thalamic) regions. Striatal and extrastriatal occupancies were correlated with dose, drug plasma levels, and with each other. Striatal D2
occupancy predicted response in positive psychotic symptoms (r¼ 0.62, p¼ 0.01), but not for negative symptoms (r¼ 0.2, p¼ 0.5).
Extrastriatal D2 occupancy did not predict response in positive or negative symptoms. The two subjects who experienced motor side
effects had the highest striatal occupancies in the cohort. Striatal D2 blockade predicted antipsychotic response better than frontal,
temporal, and thalamic occupancy. These results, when combined with the preclinical data implicating the mesolimbic striatum in
antipsychotic response, suggest that dopamine D2 blockade within specific regions of the striatum may be most critical for ameliorating
psychosis in schizophrenia.
Neuropsychopharmacology (2007) 32, 1209–1215. doi:10.1038/sj.npp.1301242; published online 1 November 2006
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INTRODUCTION
The definite mechanism of action of antipsychotic medica-
tions has not yet been established but antagonism of
dopamine transmission plays a central role. Dozens of
neuroimaging studies have documented that all antipsycho-
tics (typical and atypical; oral and injectable) block
substantial levels of striatal dopamine D2 receptors. The
general impression arising from these studies is that a
certain level of striatal dopamine D2 blockade, around 60%,
is critical for achieving an antipsychotic response and
occupancies higher than 80% are associated with motor side
effects (Farde et al, 1992; Nordstrom et al, 1993; Kapur et al,
2000). This first generation of positron emission tomo-
graphy (PET) studies of antipsychotics have focused on
measuring striatal (ie caudate and putamen) dopamine D2
occupancyFusing tracers such as [11C]-raclopride and
[11C]-NMSP with PET and [123I]-IBZM with single-photon
emission computerized tomography (SPECT). Dopamine
neurons target not only the striatum but also the limbic and
cortical areas of the brain and it has been proposed that
dopamine action in these extrastriatal (cortical and
thalamic) regions, as opposed to the striatum, may be more
relevant to antipsychotic action (Bigliani et al, 2000; Xiberas
et al, 2001a, b). The focus of this paper is to examine the
differential contributions of the dopamine D2 receptors in
the striatal vs extrastriatal regions to antipsychotic
response.
Measuring extrastriatal D2 occupancy poses a technical
challenge, as the levels of dopamine D2 receptors are much
lower (a tenth to a hundredth) in extrastriatal regions as
compared to the striatum (Kessler et al, 1993). Recently, a
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number of new tracers with very high affinity for the
dopamine D2 receptor have been developed ([
11C]-FLB
457 and [18F]-fallypride for PET and [123I]-epidepride for
SPECT) making it possible to measure extrastriatal
dopamine D2 receptors as well as their occupancy by
antipsychotics. Uncontrolled studies using these tracers
have led to interesting, but conflicting results. Some studies
have reported that atypical antipsychotics, but not typical
antipsychotics, show much higher occupancies in extra-
striatal relative to striatal regions (Xiberas et al, 2001a, b).
Other studies have failed to find such differences (Talvik
et al, 2001; Nyberg et al, 2002). Taken together, these studies
have demonstrated that it is feasible to measure striatal and
extrastriatal receptor occupancyFalthough none of these
studies randomized patients to different occupancies, used
standardized prospective treatments, or made prospective
longitudinal clinical assessments (Pilowsky, 2001; Xiberas
et al, 2001a, b).
We report here the results of the first, systematic, double-
blind, prospectively controlled study examining the rela-
tionship between striatal and extrastriatal dopamine D2
receptor occupancy and clinical outcome as measured by
(a) symptom response, (b) extrapyramidal side effects and
akathisia, and (c) prolactin elevation.
METHODS
The study was undertaken at the Centre for Addiction
and Mental Health (CAMH), a teaching hospital of the
University of Toronto. Eligible subjects were included in
the study after they provided written consent using
procedures approved by the CAMH Research Ethics Board.
The study included patients between the ages of 16 and 55
years who (1) met the DSM-IV criteria for schizophrenia,
schizoaffective, or provisional schizophreniform disorder;
(2) had never received antipsychotic treatment or had
received antipsychotic treatment for less than 4 weeks for
the current episode and had been drug free for at least 2
weeks at inclusion; (3) had a positive and negative
syndrome scale (PANSS) total score of at least 55 and
scored above 3/7 on two or above 4/7 on one of the PANSS-
positive subscale item; and (4) had no major medical or
neurological illness or history of major head injury. Subjects
were excluded if they (1) had a lifetime history of substance
dependence or a current diagnosis of substance abuse
according to DSM-IV criteria; (2) had a past history of using
clozapine or a history of poor response to olanzapine and
risperidone.
The diagnoses were established using the MINI (Mini
International Neuropsychiatric Interview for DSM-IV and
ICD-10) (Sheehan et al, 1998) based on data obtained from
the patient supplemented with information from the family
and the clinical staff. The patients, in discussion with their
treating psychiatrist, chose one of two antipsychotics
(risperidone or olanzapine). This option was given to
increase the pool of eligible patients, to respect patient
choice, and to enhance the generalizability of the results.
The patients were then randomized to the low dose
(treatment with olanzapine 2.5 mg/day or risperidone
1 mg/day) or standard dose (treatment with olanzapine
15 mg/day or risperidone 4 mg/day) condition of their
chosen medication. These doses were chosen on the basis
of previous PET occupancy data (Nyberg et al, 1995; Kapur
et al, 1997) to give a wide range of dopamine D2 occupancy.
Clinical status was assessed at baseline, on the 7th71 day
and on the 15th72 days by using the Clinical Global
Impression (CGI) Scale (Guy, 1976) for rating improvement
and the PANSS (Kay et al, 1987) for assessing clinical
symptoms. Akathisia was assessed using the Barnes
Akathisia Scale (Barnes, 1989) and parkinsonism was
quantified using the Simpson Angus Scale (SAS) (Simpson
and Angus, 1970). A rater blind to dose assignment and
the PET results assessed clinical status and side effects.
Response to treatment was defined as ‘much’ or ‘very
much’ improved on the CGI-B improvement scale (Guy,
1976).
Extrastriatal ([11C]-FLB457) and striatal ([11C]-raclo-
pride) dopamine D2 receptor occupancy were assessed after
15th72 days of continuous antipsychotic treatment 12 and
14 h after the last administered dose of antipsychotic,
respectively. PET scanning was conducted using a brain-
only PET scanner (GEMS PC2048-Plus), which provides 15,
6.5 mm-thick slices with an in-plane resolution of about
5–6 mm in air. The [11C]-FLB457 PET scans for extrastriatal
D2 receptor occupancy were obtained following injection of
9.75 (70.65) mCi of high specific-activity [11C]-FLB457 via
single bolus intravenous injection, with emission scans
collected over the next 90 min. The [11C]-raclopride PET
scans for striatal D2 receptor occupancy were obtained
immediately following injection of 9.54 (71.46) mCi of high
specific-activity [11C]-raclopride using a bolus plus infusion
protocol intravenously (Houle et al, 1996) with 59% injected
as a bolus over 1 min and the rest injected via intravenous
infusion over 74 min.
To permit accurate delineation of the brain regions for
data analysis, each patient had a magnetic resonance
imaging (MRI) scan on a GE-Sigma 1.5 T scanner using a
fast spin-echo T1-weighted sequence with 3 mm slice
thickness. The MRI scan of each patient was co-registered
to their PET scan using RView8 software (Studholme et al,
1997) and regions of interest (ROIs) were drawn using Alice
3.0 (Perceptive Systems, Boulder, Colorado), which allows
the rater to draw ROIs on the co-registered MRI image and
transfer them onto the PET images. For one subject, who
did not undergo an MRI scan, ROIs were directly delineated
on the summed PET image. The ROIs were drawn by a
single rater (blind to treatment allocation) using previously
described boundaries (Bremner et al, 1998) on two axial
slices for the cerebellum (which served as a reference
region), two axial slices for the striatum (including the
caudate and the putamen), two axial slices for the frontal
and temporal cortices, and one axial slice for the thalamus.
The ROIs were then transferred onto the dynamic PET
images using the same software and a regional time–activity
curve (TAC) generated for further analysis.
Striatal D2 receptor binding potential (BP) was calculated
using two methods, the simplified reference tissue model
(SRTM) (Lammertsma and Hume, 1996) and the ratio
method (striatum/cerebellum ratio minus one obtained
between 30 and 75 min of scanning) and taken as a measure
proportional to D2 BP. This timing was chosen based on
previous studies showing a very high correlation between
the BP derived with this method and analytically derived
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estimates of D2 BP (r40.95) (Kapur et al, 1996). The
method shows a scan-rescan SD of 6% and has been
standardized in our lab with a high intra- and inter-rater
reliability (intra-class correlation coefficients: r40.95)
(Kapur et al, 1998). Extrastriatal D2 receptor BP was
calculated from the TACs generated from the [11C]-
FLB457 scans using the SRTM, using the cerebellum as
the reference region and the frontal cortex, temporal cortex,
and thalamus as the ROIs (Lammertsma and Hume, 1996;
Olsson et al, 1999).
Receptor occupancy was then calculated as the percentage
reduction of D2 BP with drug treatment as compared to
the expected baseline (100 {1[BPdrug scan/BPExpBase-
line]}). Age-corrected measures of expected baseline BP
were obtained from a previously collected data set of 17
[11C]-raclopride scans and 13 [11C]-FLB 457 scans of
antipsychotic-free, sex- and age-matched healthy subjects.
The same rater using the same methodology to ensure
within-study consistency obtained the data for normal
controls. Venous blood was collected for plasma levels of
risperidone, 9-hydroxy-risperidone, olanzapine, and pro-
lactin at the time of the PET scans and were analyzed in
standard commercial laboratories.
Group data are expressed as mean7SD. Group differ-
ences were statistically compared using a Student’s t-test,
paired and unpaired as appropriate. Correlations between
D2 receptor occupancies and clinical outcomes were
examined using the Pearson product moment correlation.
To examine the sensitivity of the main conclusions to
individual data, each patient was dropped from the analysis,
one at a time, and the impact of that on the overall results
was examined.
RESULTS
Eighteen patients entered the study and 14 completed the
protocol. Three patients discontinued the study because of
clinical worsening; all had been randomized to the low dose
of olanzapine. One patient who was receiving low-dose
risperidone changed her mind about participating after 4
days of the study. As no PET data were available for these
patients, they were not included in the analysis. Of the 14
who completed the study, 13 were men, 10 were neuroleptic
naı¨ve, and four had 1–2 short trials of antipsychotic
medications during the year before the study. The patients
had a mean age of 27 years (range: 17–45 years) and a mean
duration of psychotic symptoms of 98 weeks (range: 4–530
weeks). Eleven of these patients met the criteria for
schizophrenia and three met the criteria for provisional
schizophreniform disorder at the time of inclusion in the
study.
The patients’ symptoms were of marked severity at the
beginning of the study as reflected by their scores on the
CGI Severity scale (mean score¼ 4.93, SD¼ 0.61), and the
PANSS (PANSS total mean¼ 79.9, SD¼ 11.4; PANSS-
positive mean¼ 21.1, SD¼ 4; PANSS-negative mean¼ 17,
SD¼ 5.3). After 1572 days of treatment, the mean percent
improvement in the PANSS total score was 17.5%79.3 and
the mean percent improvement of the PANSS-positive score
was 31.4%711.5. Five of the patients were treated with
risperidone (two at 1 mg/day and three at 4 mg/day) and
nine were treated with olanzapine (three at 2.5 mg/day and
six at 15 mg/day). At baseline, symptom severity did not
differ significantly for those on low vs standard dose or
between those treated with risperidone and olanzapine.
Two patients on risperidone were receiving benztropine
for extrapyramidal side effects at the time of the follow-up
PET scan.
The measured D2 occupancies ranged from 50 to 92% in
striatal and 4 to 95% in the different extrastriatal regions.
Occupancy in striatal and extrastriatal brain regions were
significantly higher in the standard dose group than in the
low-dose group. Striatal occupancy was significantly
correlated with frontal occupancy (r¼ 0.72, p¼ 0.005),
temporal occupancy (r¼ 0.82, po0.0001), and thalamic
occupancy (r¼ 0.81, po0.0001). Striatal occupancy
(mean¼ 71.9, SD¼ 16.7) was higher than temporal occu-
pancy (mean¼ 57.7, SD¼ 21, po0.001) and thalamic
occupancy (mean¼ 61.5, SD¼ 19, p¼ 0.005), but did not
reliably differentiate from frontal occupancy (mean¼ 65.7,
SD¼ 30.5, p¼ 0.2). The extrastriatal occupancies at the
frontal, temporal, and thalamic brain regions were not
different from each other (F¼1.019; df¼ 2; p¼ 0.376).
Striatal and extrastriatal occupancy were not correlated
with severity of illness at baselineFassuring that the
process of randomization yielded appropriate outcomes
on this variable. Percent change in PANSS-positive symp-
toms was significantly correlated with striatal occupancy
(r¼ 0.62, p¼ 0.01) (Figure 1) but not with extrastriatal
occupancy: r¼ 0.34, p¼ 0.25 (frontal); r¼ 0.30, p¼ 0.29
(temporal); r¼ 0.36, p¼ 0.20 (thalamus) (Figure 2). Percent
change in PANSS-negative symptoms was not correlated
with striatal occupancy (r¼ 0.2, p¼ 0.5) or extrastriatal
occupancy (frontal: r¼ 0.05, p¼ 0.88; temporal: r¼ 0.26,
p¼ 0.37; thalamus: r¼ 0.30, p¼ 0.29) (Figure 3).
Two patients received benztropine because of extra-
pyramidal side effects. Both of them received the standard
dose of risperidone (4 mg) and the total score of their SAS
was 13 and 8 (mean Simpson Angus total score for the
whole study subjects: 3.2 (SD¼ 3.7)). Mean striatal occu-
pancy for these two subjects was 91.5 (SD¼ 0.05), which
was significantly higher in comparison with the group of
subjects who did not have extrapyramidal side effects
(mean¼ 68.6, SD¼ 15.7) (t¼ 5.03, df¼ 11, po0.001).
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Figure 1 Relation of striatal dopamine D2 occupancy to PANSS-
positiveFrated clinical response. r¼ 0.62, p¼ 0.01.
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Analysis of the data without these two individuals showed
that the percent change in PANSS-positive symptoms was
significantly correlated with striatal occupancy (r¼ 0.6,
p¼ 0.04) but not with extrastriatal occupancy: r¼ 0.26,
p¼ 0.43 (frontal); r¼ 0.34, p¼ 0.28 (temporal); r¼ 0.31,
p¼ 0.32 (thalamus). Percent change in PANSS-negative
symptoms was not correlated with striatal occupancy
(r¼ 0.22, p¼ 0.5) or extrastriatal occupancy (frontal:
r¼ 0.01, p¼ 0.97; temporal: r¼ 0.18, p¼ 0.58; thalamus:
r¼ 0.33, p¼ 0.30).
Prolactin levels showed a trend towards correlation
with striatal occupancy (r¼ 0.47, p¼ 0.09), but there was
no observable relationship to extrastriatal D2 occupancy:
r¼ 0.4, p¼ 0.17 (frontal); r¼ 0.26, p¼ 0.36 (temporal);
r¼ 0.38; p¼ 0.17 (thalamus).
Given the small sample size, we examined the sensitivity
of these findings to individual data. Each subject was
dropped from the analysis, one at a time, and the
relationship between striatal occupancy and PANSS-P
continued to remain significant (po0.05 in all cases), and
in none of the cases did the extrastriatal correlations
become positive (p40.05 in all cases; range of p-values:
0.25–0.88). Further, to examine if the results were an artifact
of one method of BP determination, we examined the
raclopride data using the specific/nonspecific ratio method,
and the main finding of the relationship between striatal
occupancy and PANSS-P remained significant (p¼ 0.01)
and the other relationships were not significant (p40.05 in
all cases).
DISCUSSION
This is the first double-blind controlled study examining
striatal vs extrastriatal D2 occupancy and their relationship
to treatment response. As expected from previous data
(Nordstrom et al, 1993; Kapur et al, 2000), striatal
occupancy predicted improvement in positive symptoms
with antipsychotic treatment and was also associated with
motor side effects. D2 occupancy in frontal, temporal, and
thalamic regions, however, was not associated with any
measures of treatment response or side effects.
Before we discuss the possible implications of these
findings, we would like to highlight several limitations of
this study. First, the sample is small. Having acknowledged
that, it should be pointed out that the sample size was
determined on the basis of power estimates derived from
the previous studies by Nordstrom et al (1993) and Kapur
et al (2000) and the results show that the study had
sufficient power to replicate the association of striatal D2
occupancy and treatment response. Moreover, despite the
small sample size, the results did not change while using the
jackknife statistical re-sampling procedure (Efron, 1982).
The relationship (correlation or lack of correlation) between
response and occupancy remained the same even after
excluding the most extreme observations (see Figure 3).
Further, analyzing the data using two different methods for
BP determination (SRTM and specific/nonspecific ratio
method) led to identical results. A second consideration was
the relatively short duration of the study. The inclusion of a
low-dose group, and the range of occupancies it provided,
greatly increased the likelihood of demonstrating an
association between D2 occupancy and response. However,
given that the low doses used may be less than the optimal
for some of the patients, we wanted to keep the period as
short as feasible. Thus, a 2-week follow-up period was
chosen based on recently published data regarding onset of
action of antipsychotics (Agid et al, 2003; Leucht et al,
2005), which demonstrated that the improvement in the
first 2 weeks of antipsychotic treatment was significantly
higher than in any subsequent 2 weeks of treatment (Agid
et al, 2003). Although we have found a linear relationship
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Figure 2 Relation of extrastriatal dopamine D2 occupancy to
PANSS-positiveFrated clinical response. (a) Frontal occupancy (r¼ 0.34,
p¼ 0.25); (b) thalamic occupancy (r¼ 0.36, p¼ 0.2); (c) temporal
occupancy (r¼ 0.3, p¼ 0.29).
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between D2 occupancy and response, this cannot rule out
the existence of a threshold effect. However, considering the
small sample size in our study, we can neither confirm nor
eliminate this possibility.
Limitations also exist in our estimates of D2 receptor
occupancies. To estimate BP for [11C]-FLB457, we used the
SRTMFa model that assumes that the cerebellum has no
specific binding (Lammertsma and Hume, 1996). Although
the estimates of BP derived from SRTM have been shown to
be highly correlated with estimates derived from arterial-
input based kinetic-modeling, this model may under-
estimate occupancy because the humans cerebellum shows
some displaceable [11C]-FLB457 signal (Hall et al, 1996;
Olsson et al, 2004). It is estimated that the error induced by
this displaceable [11C]-FLB457 signal in the cerebellum
would range from 2 to 5% for true occupancies in the range
of 70–90% (Olsson et al, 2004). Although this may have
impacted the absolute % occupancy observed here, it is
unlikely to have changed the relative order of occupancies
observed across. We also noted that [11C]-raclopride
occupancies were higher than expectedFin our hands
similar doses in the past have led to occupancies 5–10%
lower (Kapur et al, 1999). One potential explanation might
be differences in the plasma levels of the medications during
the first ([11C]-FLB 457) and the second ([11C]-raclopride)
PET scans. However, there was no significant difference
between the plasma levels of the medications between the
two consecutive scans (t¼ 1.7; p¼ 0.11; df¼ 13). This is
likely due to the fact that the [11C]-raclopride PET scan was
performed immediately following the [11C]-FLB 457 PET
scan. The very high D2 affinity of [
11C]-FLB 457 could
lead to a residual ‘cold’ mass effect, thereby artificially
exaggerating the occupancy subsequently measured with
[11C]-raclopride. Again, although this may increase the
absolute % of raclopride measured occupancy, there is no
reason to believe this would change the internal ordering
across subjects. Finally, we did not have baseline measures
of D2 BP for the patients. This was carried out to limit the
total number of scans for the patients, especially during the
period when they were actively psychotic. As a result, we
used an adequate age- and sex-matched sample to provide
standard baseline. Lack of the patients’ own baseline values
is a potential source of error. For striatal D2 receptor
occupancy, this error, as calculated on the basis of variance
in the data from antipsychotic-naı¨ve patients, is expected to
vary from 0 to 9% for patients with 50% occupancy and 0 to
4% for patients who have 80% occupancy (Farde et al,
1992). However, there is no reason to believe that this would
introduce a systematic biasFacross ligands, or across
drug-doses, which were the main manipulations of interest
in this study (Farde et al, 1997; Bigliani et al, 2000;
Pilowsky, 2001; Xiberas et al, 2001a, b).
We found that levels of D2 receptor occupancy in the
striatum, frontal cortex, temporal cortex, and thalamus were
significantly correlated. This is consistent with a number of
previous [11C]-FLB457/[11C]-raclopride studies (Talvik
et al, 2001; Nyberg et al, 2002) and a recent [18F]-fallypride
PET study (Kessler et al, 2003) which have shown similar
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Figure 3 Relation of striatal and extrastriatal dopamine D2 occupancy to PANSS-negativeFrated clinical response. (a) Striatal occupancy (r¼ 0.2,
p¼ 0.5); (b) frontal occupancy (r¼ 0.05, p¼ 0.88); (c) thalamic occupancy (r¼ 0.30, p¼ 0.29); (d) temporal occupancy (r¼ 0.26, p¼ 0.37).
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and correlated levels of striatal and extrastriatal dopamine
D2/3 receptor occupancy. However, there are reports by
Bigliani et al (2000) and Xiberas et al (2001a, b) that atypical
antipsychotic medications demonstrated higher occupancy
of extrastriatal cortical brain regions than striatal regions.
The reason for this discrepancy between groups reporting
similar striatal-extrastriatal occupancy (this study, Talvik
et al, 2001; Nyberg et al, 2002; Kessler et al, 2003) and those
showing much higher extrastriatal occupancy (Bigliani et al,
2000; Xiberas et al, 2001a, b) are not entirely clear and have
been discussed at length elsewhere (Bigliani et al, 2000;
Talvik et al, 2001; Xiberas et al, 2001a, b; Nyberg et al,
2002). Issues such as ligand selection, ligand specificity, PET
vs SPECT, duration of scanning, non-equilibrium modeling
approaches, etc have been raised, but remain unresolved.
Regardless of this controversy, none of the previous studies
have controlled for, randomly assigned to, or examined the
relationship of striatal/extrastriatal occupancy to response.
Ours is the first study to do so. And despite a wide range of
occupancies as well as a wide range of response out-
comesFwe fail to find a relationship between extrastriatal
occupancy and response. There are two possible explana-
tions: One, a stronger relationship between extrastriatal
occupancy does exist but we failed to identify it owing to the
limitations of our study (acknowledged above), or alter-
natively, it could be that D2 occupancy in the striatum is the
mediator, not only of EPS, but also of anti-‘psychotic’
response.
It may seem surprising that response of psychosis, a
complex emotional and cognitive disturbance, may corre-
late most strongly to the actions of the drug in the striatum,
a region often thought of as just ‘motor’. However, striatal
regions impact more than just motor function and their
projections to non-motor areas of prefrontal and limbic
cortex and are optimally positioned to influence cognitive
and emotional networks (Alexander et al, 1986; de Haan,
van Bruggen et al, 2003). An example of this was found in a
recent study (de Haan, van Bruggen et al, 2003) in which D2
receptor occupancy was discovered to be correlated with
the subjective experience of patients with recent onset
schizophrenia.
Striatal regions (caudate and putamen) are now accorded
a role in the allocation of attention, selection of competing
behaviors, and in mediating the influence of motivation and
emotion on action (Mogenson et al, 1980; Joel and Weiner,
2000; Haber, 2003). Keeping with this in rodent studies, it is
well documented that antipsychotic efficacy of drugs is best
predicted by the ability of a drug to alter and/or induce
regional gene-induction, selective neuronal depolarization,
and regionally selective changes in dopamine turnover in
the nucleus accumbensFa ventral region of the striatal
complexFas opposed to changes in the dorsal striatum,
cortical, or thalamic regions (Arnt et al, 1997; Arnt and
Skarsfeldt, 1998). Unlike the rodent, the humans do not
have a clearly demarcated nucleus accumbens, but it is
thought that the region of the striatum which is anterior and
inferior to the anterior commissure is the closest analog of
the nucleus accumbens (Chronister and DeFrance, 1981).
As in our PET studies this region is captured within the
composite signal obtained from the caudate-putamen, it is
not surprising that antipsychotic response would correlated
most closely with this region.
The resolution of the PET scanner utilized in this study
did not allow us to validly differentiate between dorsal and
ventral striatum. However, post-mortem studies in humans
show that the dorsal and ventral parts of the striatum differ
from each other not only by the different afferent inputs
they receive and areas they project to (in general, dorsal
regions are linked to motor networks, the ventral regions to
limibic networks), but also by their neurotransmitter and
peptide content, their receptor distribution, their neuronal
organization, connectivity, developmental schedule, and
behavioral function (Joel and Weiner, 2000; Roberts and
Knickman, 2002; Voorn et al, 2004). The data from this
study, when combined with neuroanatomical studies as well
preclinical data all seem to lead to the hypothesis that
dopamine D2 blockade in the ventral striatum, rather than
some extrastriatal region, is the critical region for
antipsychotic response. The recent advances in high-affinity
radioligands and the increased spatial resolution of PET
scanners make this an imminently testable hypothesis.
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